CMS’s Medicare GLP-1 Bridge program is reshaping weight management pricing by setting a flat $50 monthly copay point for eligible beneficiaries through December 31, 2027. The program runs outside traditional Medicare Part D mechanics, according to CMS, with a centralized claims and prior-authorization infrastructure. Major retail pharmacy chains have aligned around the Bridge signal, including CVS, Walgreens, Amazon Pharmacy, and Publix. Novo Nordisk and Eli Lilly are positioned within the framework for Wegovy and Zepbound (and Foundayo in related coverage pathways), while the program excludes patients with type 2 diabetes. The pricing structure is already influencing service design, digital eligibility workflows, and pharmacy support models as manufacturers and providers adapt to a predictable monthly cost signal. For payers, care delivery platforms, and manufacturers, the program creates a near-term market reconfiguration around adherence support and access pathways.